Journal of Oncology Pharmacy Practice

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for more information

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wiernikowski, J.
Right arrow Articles by Atkinson, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wiernikowski, J.
Right arrow Articles by Atkinson, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Oncology Pharmacy Practice, Vol. 11, No. 2, 51-56 (2005)
DOI: 10.1191/1078155205jp145oa
© 2005 SAGE Publications

Alendronate for steroid-induced osteopenia in children with acute lymphoblastic leukaemia or non-Hodgkin’s lymphoma: results of a pilot study

JT Wiernikowski, BScPhm, PharmD

McMaster Children’s Hospital, Hamilton, Ont., Canada

RD Barr, MD

McMaster Children’s Hospital, Hamilton, Ont., Canada, Department of Pediatrics, McMaster University, Hamilton, Ont., Canada

C Webber, PhD

Department of Nuclear Medicine, Hamilton Health Sciences, Hamilton, Ont., Canada

CY Guo, PhD

Department of Pediatrics, McMaster University, Hamilton, Ont., Canada

M Wright, BSc PT, MEd

McMaster Children’s Hospital, Hamilton, Ont., Canada, Department of Pediatrics, McMaster University, Hamilton, Ont., Canada

SA Atkinson, PhD

McMaster Children’s Hospital, Hamilton, Ont., Canada, Department of Pediatrics, McMaster University, Hamilton, Ont., Canada

Background/objectives. Osteopenia is a significant morbidity in children undergoing therapy for acute lymphoblastic leukaemia (ALL) or non-Hodgkin’s lymphoma (NHL). We conducted a pilot study to assess the impact of alendronate on whole body bone mineral content (WB-BMC), lumbar spine bone mineral density (LS-BMD), biochemical measures of bone mineral metabolism, as well as gross motor function and health-related quality of life (HRQL) in children undergoing therapy for ALL or NHL.

Methods. Ten children (nine boys) between the ages of 3.6 and 14.6 years, on identical maintenance chemotherapy for ALL or NHL were treated with oral alendronate once weekly, and daily calcium supplementation, for a period of six months. Outcome measures were WB-BMC and LSBMD; biochemical measures of bone mineral metabolism including plasma osteocalcin, C-terminal telopeptide of type I collagen (CTx), serum calcium, 25-hydroxy-vitamin D (25-OHD), and parathyroid hormone (PTH); as well as assessments of motor function and HRQL.

Results. A gain in Z score was observed in 7/9 evaluable patients for WB-BMC (mean increase of 0.49) and LS-BMD (0.51). Plasma osteocalcin and CTx showed a change in bone turnover favouring formation over resorption. Serum calcium and 25- OHD remained normal throughout treatment. After an initial spike, serum PTH returned to baseline values at week 4. Measures of motor function showed some improvement and there were modest gains in HRQL.

Conclusions. Alendronate therapy was tolerated well. Further study in a larger sample of children with ALL or NHL is warranted, in the context of a randomized clinical trial.

Key Words: acute lymphoblastic leukaemia (ALL) • bisphosphonates • morbidity • osteopenia • paediatrics • quality of life


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?